




Available online at
ScienceDirect
www.sciencedirect.com

Elsevier Masson France
EM|consulte
www.em-consulte.com/en



Original article

Evaluation of halitosis using OralChroma™ in patients with allergic rhinitis

M.O. Avincsal^{a,*}, A. Altundag^b, M.E. Dinc^a, M. Cayonu^c, M. Topak^a, M. Kulekci^a

^a Department of Otorhinolaryngology, Gaziosmanpaşa Taksim Training and Research Hospital, Karayolları Mahallesi, Osmanbey Caddesi, No. 120, Gaziosmanpaşa, Istanbul, Turkey

^b Taste and Smell Clinic, Istanbul Surgery Hospital, Ferah Sok, No. 22 Şişli, TR-34365 Istanbul, Turkey

^c Department of Otorhinolaryngology, Amasya University S.S. Training and Research Hospital, 05100 Kirazlıdere, Amasya, Turkey

ARTICLE INFO

Keywords:

Halitosis
Volatile sulphur compounds
OralChroma™
Allergic rhinitis

ABSTRACT

Objective: The objective of this study was to evaluate the occurrence of halitosis in patients with allergic rhinitis (AR).

Materials and methods: In this study, we enrolled 53 patients with AR and 34 participants as controls. Halitosis was evaluated by measuring volatile sulphur compound (VSC) levels. VSCs, which consist of hydrogen sulphide (HS), methyl mercaptan (MM), and dimethyl sulphide (DMS), were measured using a portable gas chromatograph (OralChroma™; AbiMedical, Osaka, Japan).

Results: Patients with AR exhibited significantly higher levels of MM and DMS than control subjects. Specifically, MM levels showed a greater increase than DMS levels in patients with AR than in controls. We observed no significant changes in the levels of HS between the groups.

Conclusion: This study demonstrated that AR is likely to result in halitosis. Several studies have overlooked the relationship between halitosis and AR. In light of our results, we suggest that halitosis should be further investigated in patients with AR.

© 2016 Elsevier Masson SAS. All rights reserved.

1. Introduction

Allergic rhinitis (AR) is a common inflammatory disease that affects 10 to 25% of the population worldwide [1]. Patients with AR experience a decreased quality of life associated with typical AR symptoms (i.e., sneezing, pruritus, nasal obstruction, and rhinorrhoea) and issues such as smell-taste disorders, halitosis, fatigue, malaise, and possible neurocognitive deficits [2,3].

Halitosis is an unpleasant, offensive odour spreading from the oral cavity and is commonly known as 'bad breath'. It is a very common complaint among patients who visit otolaryngology clinics. When severe or long-standing, it may lead to personal discomfort and social embarrassment, thus impacting the quality of life in a negative manner. The causative agents of halitosis are the oral cavity (90%), the respiratory tract (8%), and the gastrointestinal tract, including other organs (2%) [3]. Halitosis associated with the oronasal cavity may be due to post-nasal drip, pharyngitis, tonsillitis, deep crypts of the tonsils, sinusitis, a foreign body in the nasal or sinus cavity, and ozena. These pathologies cause halitosis because of bacteria, which cause putrefaction of the tissues and

production of volatile sulphur compounds (VSCs), the main components of human oral malodour [4]. Several studies have noted the association between AR and halitosis. Nasal allergies cause excess mucus production in the nose and sinus cavities, which leads to post-nasal drip. It is hypothesised that as nasal discharge slides down the back of the throat, it can give oral bacteria a place to multiply, leading to the characteristic 'bad breath' [3,5]. However, few studies have supported or refuted this conjecture. Therefore, the goal of this study was to determine the potential effects of AR on oral malodour production using a portable gas chromatograph (OralChroma™; AbiMedical, Osaka, Japan) [6]. To the best of our knowledge, this is the first study to investigate halitosis in patients with AR.

Both halitosis and AR can negatively affect the quality of life of an individual. We believe that these conditions have been understudied. Therefore, in this study, we decided to evaluate the occurrence of halitosis in patients with AR.

2. Materials and methods

2.1. Subject selection

This study involved 87 subjects (53 patients with AR and 34 participants as controls), with a mean age of 36 ± 1 years (range:

* Corresponding author. Tel.: +90 212 945 3000.
E-mail address: ozgur.tr@hotmail.com (M.O. Avincsal).

Table 1
Descriptive statistics of the study groups.

	Allergic rhinitis, n = 53	Control group, n = 34	P-value
Age	36.9 ± 1.2	36.5 ± 1.5	0.6
Gender (F/M)	33/20	20/14	0.5
Hydrogen sulfide level	14.4 ± 19.9	17.2 ± 22.2	0.6
Methyl mercaptan level	121.5 ± 116	2.6 ± 5.5	< 0.001
Dimethyl sulfide level	6.6 ± 11.1	0.3 ± 1.2	< 0.001

18–47 years). All participants confirmed that they were not suffering from any known diseases and that they were not receiving any medical treatment. Participants with a previously diagnosed systemic disease and an additional disease that may cause halitosis, such as radiotherapy to head and neck, chemotherapy, major head and neck surgery, chronic sinusitis, nasal polyposis, or clinically significant nasal septal deviation, were excluded from this study. For all patients, a standardised oral examination was performed by the same dentist. Patients with obvious gingival inflammation, gingivitis, advanced periodontitis, active or severe caries, substantial false dentition, and oral thrush were excluded. The age- and sex-matched control groups comprised individuals who were admitted to the otolaryngology clinic for other reasons, but still met the above criteria (Table 1).

The survey was conducted according to the principles expressed in the Helsinki Declaration and was approved by the Clinical Trials Committee of the Gaziosmanpaşa Taksim Training and Research Hospital. The details of the study protocol were explained to all subjects, and written informed consent was obtained prior to participation.

2.2. Assessment of allergic rhinitis

The study group, namely patients with AR, were enrolled in the Department of Otorhinolaryngology of the Gaziosmanpaşa Taksim Training and Research Hospital (İstanbul, Turkey). All patients had the following characteristics: a diagnosis of AR based on history, physical examination and allergy tests, and sensitivity to at least 1 or at most 3 of the tested allergens. The individuals in the control group had a similar allergy exam, but tested negative for allergies. All patients using any AR medication, including intranasal steroid or antihistaminic drugs, were excluded from the study.

2.3. Measurement of sulphur compound levels

VSCs comprise hydrogen sulphide (HS), methyl mercaptan (MM), and dimethyl sulphide (DMS) and were measured using a portable gas chromatograph (OralChroma™; AbiMedical, Osaka, Japan) [7,8]. All participants were instructed about the procedure involved in this study. The participants were required to avoid foods associated with oral malodour (i.e. garlic, onions and spicy food) 1 day prior to the study. Twelve hours before we VSC measurements were obtained, the participants had to refrain from drinking alcohol or coffee and from smoking. On the evening prior to the day of testing, the participants were instructed to perform their normal oral hygiene routine. The morning of their assessment, patients were required to avoid food intake as well as chewing gum, mints, drops, scents, and mouth rinses. Alternatively, tooth brushing with water was permitted to avoid morning 'bad breath'. All measurements were recorded in the morning between 8:30 and 11:30 AM by the same breath specialist. Exhaled gas samples were collected with disposable syringes (1-ml plastic syringes), which were inserted into the volunteers' oral cavities. Subjects had to close their mouth for 30 s prior to the sample collection. A volume of 0.5 ml of mouth air was injected into the inlet on the main unit of the OralChroma™. Measurements were started automatically;




Fig. 1. Box plot model graphing of dimethyl sulfid (DMS) levels according to the study groups. There was a significant difference between the study groups in terms of DMS levels ($P < 0.001$).

the process was completed after 8 min, and the concentrations of the three gases were displayed in units of either ng/10 ml or ppb (nmol/mol). All the measurements were repeated for 3 times to improve the reliability of the study, and also each concentration measured by the OralChroma™ was finally determined with analysis software (OralChroma™ Data Manager, AbiMedical, Osaka, Japan) for the validation of data.

2.4. Statistical analysis

Data analyses were performed using the Statistical Package for the Social Sciences, version 21.0 (SPSS; IBM Corp., Armonk, NY, USA). The normal distribution of the considered variables was first evaluated using the Shapiro–Wilk test. The data are presented as the mean with standard deviation for continuous variables and as the number of cases for categorical variables. The differences between the groups were analysed by a t -test or the χ^2 test, as appropriate.

3. Results

In this study, we enrolled 54 patients with AR. There was no significant difference in age or sex between the AR and control groups (Table 1). The skin prick test results were evaluated for patients with AR. The prick test evaluated the following six main allergens: *Alternaria* spp. (mould fungus), members of the Oleaceae family (olive tree), *Secale cereale* (rye), *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae* (dust mites), and graminoids (grasses). Among all patients with AR, 46% were allergic to *D. pteronyssinus*, 34% were allergic to *D. farinae*, 38% were allergic to *Alternaria* spp., and 31% were allergic to graminoids.

As shown in Table 1, we observed significantly higher levels of DMS and MM in the patients with AR than in the control subjects (Figs. 1 and 2). This increase was most significant for the MM levels (Fig. 2). No significant changes in the HS levels were detected between the two groups (Fig. 3).

4. Discussion

AR is a global health problem. Several studies have indicated an increase in the prevalence of AR over the last four decades. This increase has been mostly observed in both industrialised and developing countries [9]. The World Health Organization estimates that approximately 20% of the world's population suffers from AR. Furthermore, it can be a considerable source of morbidity in poorly managed patients. AR can impair social and work functions and




Fig. 2. Box plot model graphing of methyl mercaptan (MM) levels according to the study groups. There was a significant difference between the study groups in terms of MM levels ($P < 0.001$).

significantly affect an individual's quality of life. One or more of the following symptoms may negatively impact the quality of life: sneezing, rhinorrhoea, itching, and nasal congestion. Another possibility is the association between AR and halitosis.

Halitosis is generally diagnosed by three main methods: organoleptic examination, sulphide monitoring, and gas chromatography. Organoleptic examination is a sensory test scored on the basis of the examiner's perception of a subject's oral malodour. In this study, we did not use this method; instead, we used an objective method that evaluates halitosis by measuring VSC levels. Sulphide monitors such as the Halimeter (Interscan Co., Chatsworth, CA) can analyse the total sulphur content of a subject's mouth air. However, one limitation of the Halimeter is its inability to differentiate between the three VSCs, which are the main components of human oral malodour [7,10]. Gas chromatography is considered the gold standard for measuring oral malodour because of its ability to specifically analyse VSCs [6,11]. In this study, a portable gas chromatograph, the OralChroma™, was used to measure the VSCs of morning mouth air taken from each subject. A recent study demonstrated that the portable gas chromatograph utilised in this study can measure the concentrations of the VSCs in mouth air as well as diagnose halitosis [8].

Halitosis has a significant socioeconomic impact and may reveal underlying disease in individuals diagnosed with this condition. It may lead to personal discomfort and social embarrassment, thus impacting the quality of life in a negative manner. Until

recently, halitosis was neglected by scientists and clinicians and was hardly covered in medical curricula. To date, no study has analysed the relationship between the level of VSCs in mouth air and the occurrence of AR. One possible reason for this is that until recently, portable gas chromatographs were unavailable. However, the OralChroma™ and other portable gas chromatographs are now available, which has made it possible to obtain VSC data outside of a clinical setting. Another possible reason for this is that halitosis was often neglected by the AR patients in comparison with the typical AR symptoms (i.e., sneezing, pruritus, nasal obstruction, and rhinorrhoea).

VSCs are the main components of 'bad breath'. VSCs comprise HS, MM, and DMS [7]. HS and MM typically originate from microbial putrefaction within the oral cavity. Alternatively, DMS is thought to originate from the lung and to be related to systemic diseases, although the relationship between the DMS level and systemic disease needs further investigation [12]. In the present study, we observed higher MM and DMS levels in patients with AR than in control subjects. In patients with AR, the concentration of MM was much greater than that of the other two gases when compared with the control subjects. However, there was no significant difference in the HS level between the patients with AR and the control group. Nasal allergies can cause excess mucus production in the nose and sinus cavities, leading to post-nasal drip. As nasal discharge slides down the back of the throat, it can give oral bacteria a place to multiply, leading to characteristic 'bad breath'. In a previous study, patients with halitosis and high MM levels had higher bacterial loads of *Prevotella*, *Veillonella*, *Atopobium*, *Megasphaera*, and *Selenomonas* in their oral microbiota [13]. Thus, post-nasal drip may cause these types of species to accumulate in the microbiota, resulting in the increase in MM levels observed in patients with AR. However, the exact relationship between AR and increased MM levels is still unknown. Therefore further investigations on oral microbiota of patients with AR should be required to stress the relation between MM levels and AR. This study is the first to report a positive relationship between halitosis and AR.

Individuals with halitosis are typically unaware of their malodour. This unawareness stems from olfactory desensitisation, which occurs in individuals with halitosis [14]. In a previous study, odour threshold scores were lower in participants with halitosis than in control subjects [15]. This may also be explained by the toxic effects of the VSCs on chemosensory receptors. As a result, chemosensory disorders in patients with AR is mainly caused by the mucosal edema, however it may be also a result of increased VSC levels. Thus, the toxic effects of VSCs on chemosensory receptors in patients with AR should be further investigated.

VSCs could contribute to the etiopathogenesis of AR. However, future studies will be necessary to determine the underlying mechanisms. Because toxic doses of MM can cause severe headaches, it is possible that the high levels of MM we observed in the patients with AR in this study were related to the headaches that occur in AR.

One of the possible limitations of this study was the lack of organoleptic scoring (OLS) of the participants. Whereas, the available literature shows that the measurement of VSCs with a portable gas chromatograph can be accepted as a gold standard for diagnosing halitosis and it has a high correlation with OLS [7,8].

Disclosure of interest

The authors declare that they have no competing interest.

References

- [1] Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in




Fig. 3. Box plot model graphing of hydrogen sulfid (HS) levels according to the study groups. There was no significant difference between the study groups in terms of HS levels ($P = 0.6$).

- childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. *Lancet* 2006;368(9537):733–43.
- [2] Rydzewski B, Pruszewicz A, Sulkowski WJ. Assessment of smell and taste in patients with allergic rhinitis. *Acta Otolaryngol* 2000;120(2):323–6.
 - [3] Bollen CM, Beikler T. Halitosis: the multidisciplinary approach. *Int J Oral Sci* 2012;4(2):55–63.
 - [4] Tagerman A. Halitosis in medicine: a review. *Int Dent J* 2002;52(Suppl. 3): 201–6.
 - [5] Tonzetich J. Production and origin of oral malodor: a review of mechanisms and methods of analysis. *J Periodontol* 1977;48:13–20.
 - [6] Tagerman A, Winkel EG. The portable gas chromatograph Oral Chroma™: a method of choice to detect oral and extra-oral halitosis. *J Breath Res* 2008;2(1):017010.
 - [7] Dadamio J, Laleman I, De Geest S, et al. Usefulness of a new malodour-compound detection portable device in oral malodour diagnosis. *J Breath Res* 2013;7(4):046005.
 - [8] Murata T, Rahardjo A, Fujiyama Y, et al. Development of a compact and simple gas chromatography for oral malodor measurement. *J Periodontol* 2006;77(7):1142–7.
 - [9] Rutkowski K, Sowa P, Rutkowski R. Allergic diseases: the price of civilisational progress. *Postepy Dermatol Alergol* 2014;31(2):77–83.
 - [10] Awano S, Ansai T, Takata Y, et al. Relationship between volatile sulfur compounds in mouth air and systemic disease. *J Breath Res* 2008;2(1): 017012.
 - [11] Awano S, Takata Y, Soh I, et al. Correlations between health status and OralChroma™ determined volatile sulfide levels in mouth air of the elderly. *J Breath Res* 2011;5(4):046007.
 - [12] Tagerman A, Winkel EG. Intra- and extra-oral halitosis: finding of a new form of extra-oral blood-borne halitosis caused by dimethyl sulphide. *J Clin Periodontol* 2007;34(9):748–55.
 - [13] Takeshita T, Suzuki N, Nakano Y, et al. Discrimination of the oral microbiota associated with high hydrogen sulfide and methyl mercaptan production. *Sci Rep* 2012;2:215.
 - [14] Stuck BA, Fadel V, Hummel T, et al. Subjective olfactory desensitization and recovery in humans. *Chem Senses* 2014;39(2):151–7.
 - [15] Altundag A, Cayonu M, Kayabasoglu G, et al. The evaluation of olfactory function in individuals with chronic halitosis. *Chem Senses* 2015;40(1): 47–51.